IGF-1 vs IGF-1 LR3: What the Research Compares

The short answer on naming

Recombinant human IGF-1 (mecasermin) is a prescription medicine authorised by regulators in the United States and the European Union for severe primary IGF-1 deficiency, while IGF-1 LR3, also written long R3 IGF-1, sits at the preclinical and laboratory stage of development and appears in the published record as a research protein and a cell culture supplement. The two names therefore describe overlapping but distinct molecules: one is the native 70 amino acid human hormone produced recombinantly, and the other is an engineered analogue of that same hormone.

Both molecules act on the same receptor system, which is why the literature on them reads as one family rather than two unrelated compounds. Work producing both proteins in Pichia pastoris described LR3 IGF-1 as an analogue of IGF-1 carrying an arginine substitution at position 3 together with a 13 residue N terminal extension, and researchers in that study expressed both forms as xylanase fusions and assessed their bioactivity after cleavage (PMID 37261455). The structural changes in the analogue are the reason the two are studied under separate names at all.

Side by side: class, status and evidence base

Is there a head-to-head comparison?

No direct head-to-head comparison of IGF-1 and IGF-1 LR3 exists in the verified literature for this page. There is no trial in which the same participants or the same animals received both molecules under matched conditions with a shared primary endpoint. Any statement that one form outperformed the other would therefore be an inference across separate studies rather than a reported result.

The nearest adjacency is the late gestation fetal sheep model, where both molecules have been infused in separate experiments with overlapping outcome measures. A 2021 study reported that IGF-1 infusion to fetal sheep increased organ growth without stimulating nutrient transfer to the fetus (PMID 33427051), whereas a 2025 study in the same species reported that IGF-1 LR3 did not promote growth in late gestation growth restricted fetal sheep (PMID 39679943). Those two reports used different fetal conditions, normal versus growth restricted, so they sit side by side rather than in direct opposition.

What published studies measured for IGF-1

Growth and organ outcomes

Researchers infusing IGF-1 into late gestation fetal sheep reported increased organ growth while placental nutrient transfer to the fetus was not the mechanism responsible, which pointed analysis toward direct tissue level effects (PMID 33427051). A 2020 study in the same species reported that coronary vascular growth matched IGF-1 stimulated cardiac growth, meaning that the vascular supply expanded in proportion to the enlarged myocardium rather than lagging behind it (PMID 32573852).

Signalling pathways

Earlier cell work in fetal sheep cardiomyocytes reported that extracellular signal regulated kinase and phosphoinositol 3 kinase pathways mediated IGF-1 induced proliferation, identifying the intracellular routes through which the hormone drove cell division in that preparation (PMID 12947030). Separate laboratory work in Chinese hamster ovary cells reported that N linked glycosylation was critical for insulin-like growth factor 1 signalling, a finding relevant to how receptor function is studied in engineered cell lines (PMID 36499281).

Pancreatic and metabolic endpoints

A 2021 fetal sheep study reported that glucose stimulated insulin secretion was reduced following a one week IGF-1 infusion in late gestation, and the study attributed the change to an intrinsic islet defect rather than to circulating factors (PMID 33938236). That result is one of the clearest examples in the verified set of an endocrine effect extending beyond growth outcomes.

What published studies measured for IGF-1 LR3

Fetal growth and insulin secretion

The 2025 fetal sheep study reported that IGF-1 LR3 did not promote growth in late gestation growth restricted fetuses, an outcome the authors framed against expectations drawn from the native hormone (PMID 39679943). A 2023 study in the same model reported that glucose stimulated insulin secretion was attenuated during an acute IGF-1 LR3 infusion into fetal sheep, yet that attenuation did not persist when islets were isolated and tested outside the animal (PMID 37114757). Placed next to the one week IGF-1 infusion result, where researchers reported an intrinsic islet defect (PMID 33938236), the two reports illustrate how exposure duration and molecular form can both shape what is observed.

Tissue repair and neurological models

A 2025 materials science study incorporated controlled IGF-1 LR3 release into a decellularized Alstroemeria stem based nerve conduit combined with GelMA and reported enhanced rat sciatic nerve regeneration compared with the control conduits used in that work (PMID 41015370). In a different direction, researchers reported that intranasal long R3 IGF-1 treatment promoted amyloid plaque remodeling in the cerebral cortex of male 5XFAD mice but failed to preserve cognitive function in the same animals (PMID 39610283). Those two reports show the analogue being tested as a delivered biologic in disease models rather than as a systemic growth agent.

Production and laboratory use

The recombinant expression study produced both IGF-1 and LR3 IGF-1 as xylanase fusion proteins in Pichia pastoris and evaluated the bioactivity of the released peptides, work aimed at manufacturing routes for research and biotechnology supply (PMID 37261455). This production context explains why the analogue appears so often in cell culture and bioprocessing settings.

Metabolic and safety observations: what studies report

The verified animal literature contains repeated signals around glucose handling for both forms. Researchers reported attenuated glucose stimulated insulin secretion during acute IGF-1 LR3 infusion in fetal sheep, with the effect absent in isolated islets (PMID 37114757), and reported reduced glucose stimulated insulin secretion attributable to an intrinsic islet defect after a one week IGF-1 infusion in the same model (PMID 33938236). A 2026 review of performance enhancing peptides acting on the growth hormone and IGF-1 axis described a gap between the clinical evidence base and patterns of patient self administration, and the authors framed that gap as a clinical safety concern for prescribers assessing patients (PMID 42395176). None of these reports establishes a human adverse event profile for the analogue, and questions about risk in any individual belong with a prescribing clinician.

Why the two evidence bases are hard to compare

• Different species and conditions. Growth outcomes were reported in normally growing fetal sheep for IGF-1 (PMID 33427051) and in growth restricted fetal sheep for IGF-1 LR3 (PMID 39679943).
• Different delivery routes. The analogue has been studied by infusion, by intranasal delivery in mice (PMID 39610283) and by controlled release from an implanted conduit in rats (PMID 41015370).
• Different endpoints. Cardiac and coronary measures (PMID 32573852), proliferation signalling (PMID 12947030) and receptor glycosylation (PMID 36499281) each answer narrow mechanistic questions.
• Different regulatory contexts. One form is an approved prescription product with a defined indication, and the other remains a laboratory and preclinical research protein.

How to read this comparison

The literature summarised here supports description, not ranking. The published work reports what happened in specific species, at specific developmental stages, with specific delivery methods, and the studies were not designed to crown a preferred molecule. Where a reader is weighing anything related to IGF-1 biology, the relevant regulated product is the approved prescription medicine and the relevant decision maker is a licensed physician who can review individual history, laboratory values and indications.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, condition or treatment, including anything involving the growth hormone and IGF-1 axis.

Related reading

• IGF-1: what the literature describes
• IGF-1 LR3: what the literature describes

References

• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology: Endocrinology and Metabolism, 2025)
• N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling (International Journal of Molecular Sciences, 2022)
• Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep (FASEB Journal, 2020)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus (American Journal of Physiology: Endocrinology and Metabolism, 2021)
• Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect (American Journal of Physiology: Endocrinology and Metabolism, 2021)
• Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 2003)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration (International Journal of Biological Macromolecules, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)